AGR2 and Charcot-Marie-Tooth disease: Importantly, anti-AGR2 and anti-IGFBP5 levels were significantly higher in the malignant CMT group compared with the benign CMT group (Figure 3), suggesting their potential as serum biomarkers for CMT malignancy.